Posts

Parabilis reveals IPO plans the day after Regeneron deal as listings heat up

Parabilis Medicines has filed for an IPO seeking up to $100 million just one day after announcing a major strategic collaboration with Regeneron worth up to $2.3 billion. Under the Regeneron deal, Parabilis will receive $50 million upfront and Regeneron has committed to invest $75 million in Parabilis’s next equity financing, which is being structured as part of the IPO raise. The biotech plans to use IPO proceeds to advance its lead helicon‑peptide candidate zolucatetide (FOG‑001) into a global registrational Phase III trial in desmoid tumors, expand its broader pipeline, and fund its Helicon platform and general corporate purposes. Parabilis will list on Nasdaq under the ticker symbol PBLS, with underwriters including Leerink Partners, BofA Securities, and Evercore ISI. The IPO filing underscores a broader uptick in biotech listings, as investors show renewed appetite for companies with validated platforms and corporate partnerships from large‑pharma partners like Regeneron. ...

BioMarin Suffers Another Blow to Rare Disease Portfolio in Phase 3 Flop

AbbVie’s Skyrizi yields to UCB’s Bimzelx in psoriatic arthritis head‑to‑head trial

Prasad ally Szarama exits CBER after 3 weeks as FDA cleanout continues

Wave aims for monthly dosing with RNA editing treatment for AATD now targets a monthly injection schedule for its WVE‑006 program in AATD.

TrumpRx adds more than 600 generic meds, building on one success in US pricing

ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease

Zydus Lifesciences to Pursue Acquisitions in Specialty and Rare Diseases

Takeda faces possible $2.5 billion damages in Amitiza pay‑for‑delay case

Akeso Spotlights AML Data for Anti‑CD47 mAb Ahead of EHA 2026

BioMarin's rare disease therapy shows no clinical benefit in Phase 3 test

Relay presses ahead on PI3Kα inhibitor after first phase 2 data in vascular (blood vessel) disorder

SEED Therapeutics to Present Phase 1 Trial Design for ST-01156, a First-in-Human Oral RBM39 Molecular Glue Degrader, at 2026 ASCO Annual Meeting